Also, it reported that PAD4 levels are associated with earlier disease onset, and that these levels decrease after three months of treatment with disease-modifying antirheumatic drugs (DMARDs), indicating that anti-PAD treatment could potentially be beneficial in RA [28]. Here, PADI4 is linked to peripheral arterial disease.